AZ and MSD's Lynparza gets fast prostate cancer FDA review

The FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the heels of rival Clovis and its Rubraca and targeting a wider patient

Clovis takes PARP prostate cancer pole position with fast FD...

The FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate cancer, the first drug in this class to target the indication.

AZ sells ex-US rights to old cancer drugs Arimidex and Casod...

For several years AstraZeneca has been selling off rights to its older drugs to raise cash as it develops a new generation of drugs, and this pattern has continued as it sold its Arimidex a

Xtandi catches up with Erleada in castration-sensitive prost...

Merck & Co's Keytruda shows promise with prostate cancer 'su...

A small proportion of men with advanced prostate cancer, who have exhausted all other treatment options, were ‘super responders’ to Merck & Co’s Keytruda (pembrolizumab) immunotherapy i

FDA approves J&J's prostate cancer drug Erleada in new use, ...

The FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has spread.